130 filings
Page 2 of 7
8-K
c78zbu19ztjf2jlasf
10 May 22
Intra-cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:37am
8-K
6yx3pn3ebhkpe7z
25 Apr 22
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
7:12am
8-K
dsldob
21 Apr 22
Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors
8:08am
8-K
7yra84fk7iug6s
1 Mar 22
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2021 Financial Results and Provides Corporate Update
7:49am
8-K
nxyi pdyz172k5
7 Jan 22
Other Events
4:12pm
8-K
vwyln9ckez
5 Jan 22
Entry into a Material Definitive Agreement
5:06pm
8-K
69xgz9b1807goma2gi04
5 Jan 22
Financial Statements and Exhibits
4:58pm
8-K
c5po36cs35u8oxu6
4 Jan 22
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
12:00am
8-K
4v3pdrxe 8b
29 Dec 21
Entry into a Material Definitive Agreement
4:11pm
8-K
tkkfj
20 Dec 21
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
7:04am
8-K
lc8x3zf7
8 Dec 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:33pm
8-K
v8ys9 cweqr0c0zx
9 Nov 21
Intra-cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:49am
8-K
u7pzugsy5f4jef ojljn
9 Aug 21
Intra-cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
jexy8iupks2i2
22 Jun 21
Amendments to Articles of Incorporation or Bylaws
4:09pm
8-K
8bpt2dleot632
10 May 21
Intra-cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
z7umk7eehurebp2
3 May 21
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
7:42am
8-K
24yo2
25 Feb 21
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2020 Financial Results and Provides Corporate Update
7:54am
8-K
wzjdr14u7l24aw 2cul
22 Feb 21
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
8:09am
8-K
h4de xkrc
9 Nov 20
Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:40am
8-K
eealvw 80e4xksj6w
1 Oct 20
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
4:38pm